Sentences with phrase «number of cell therapies»

Fueled by a recent resurgence in public financing and compelling clinical data for indications as diverse as acute macular degeneration and pancreatic cancer, a growing number of cell therapies are driving toward pivotal clinical studies and commercialization.

The number of cell therapies currently in phase 2 and phase 3 development and delivering promising results, however, evidences the industry's advancement toward a commercial state.

Not exact matches

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

For the present, of course, even somatic cell therapies will be very few, but their number will grow.

Despite the presumed virulence of the strain — experiments with mouse lungs showed it produces 1000 times more bacteria in infected cells than do standard varieties — Valway says the number of TB cases that developed were kept in line with other typical outbreaks, which «shows that doing good contact investigations is important and preventative therapy works.»

«The results show we can now produce the number of cells needed for human therapy and get formation of new heart muscle on a scale that is relevant to improving the function of the human heart,» Laflamme said.

In an effort to expand the number of cancer gene mutations that can be specifically targeted with personalized therapies, researchers at University of California San Diego School of Medicine and Moores Cancer Center looked for combinations of mutated genes and drugs that together kill cancer cells.

On the flipside, targeting this growth factor or BCL - 2 could reduce NK cell numbers and offer potential therapies for immune disorders such as some types of autoimmune diseases, sepsis or graft versus host disease, a side effect of bone marrow transplants.

The number of extracted tumor cells allows conclusions to be drawn with respect to the success of therapy and the future course of the disease.

The researchers conclude this technique could eventually lead to new ways to prepare vast numbers of cells for the coordinated manufacture of gene therapies.

As in the former case, after being treated with telomerase gene therapy «the telomeres in the peripheral blood in these mice also lengthened and the number of blood cells increased considerably,» write the authors.

Knowing which cells are best for the therapy should not only improve patient outcome, but also reduce the number of cells required, which would further reduce both the time of the preparation and invasiveness of the procedure.

However, these therapies often fail because insufficient numbers of T cells reach the tumor.

But if even a small number of mutant mitochondria are retained after the transfer — a common occurrence — they can outcompete healthy mitochondria in a child's cells and potentially cause the disease the therapy was designed to avoid, experiments suggest.

Robert Beall becomes CEO of the CFF and, grasping the limitations of gene therapy, invests $ 3.2 million in Aurora Biosciences Corp., where cell physiologist Paul Negulescu begins to look for a chemical cure using high - throughput methods to test large numbers of potential drugs.

A number of research teams are putting other experimental stem cell therapies through stringent clinical trials.

This is both a useful tool for giving us a better understanding of the genetic and epigenetic program controlling the self - renewal of stem cells, and on a practical side, it could allow us to inexpensively produce large numbers of immune cells, which could then be used for regenerative medicine or immune therapy.»

The ability to make expand the number of iNKT cells is expected to advance cancer therapies.

«The successful retrieval of memories in AD mice by increasing the number of spines for normal memory processing only in the memory cells, rather than in a broad population of cells, highlights the importance of highly - targeted manipulation of neurons and their circuits for future therapies.

Research into Stem Cells has grown exponentially over the past two decades and has already yielded successful or promising therapies for a number of diseases.

g (acceleration due to gravity) G (gravitational constant) G star G1.9 +0.3 gabbro Gabor, Dennis (1900 — 1979) Gabriel's Horn Gacrux (Gamma Crucis) gadolinium Gagarin, Yuri Alexeyevich (1934 — 1968) Gagarin Cosmonaut Training Center GAIA Gaia Hypothesis galactic anticenter galactic bulge galactic center Galactic Club galactic coordinates galactic disk galactic empire galactic equator galactic habitable zone galactic halo galactic magnetic field galactic noise galactic plane galactic rotation galactose Galatea GALAXIES galaxy galaxy cannibalism galaxy classification galaxy formation galaxy interaction galaxy merger Galaxy, The Galaxy satellite series Gale Crater Galen (c. AD 129 — c. 216) galena GALEX (Galaxy Evolution Explorer) Galilean satellites Galilean telescope Galileo (Galilei, Galileo)(1564 — 1642) Galileo (spacecraft) Galileo Europa Mission (GEM) Galileo satellite navigation system gall gall bladder Galle, Johann Gottfried (1812 — 1910) gallic acid gallium gallon gallstone Galois, Évariste (1811 — 1832) Galois theory Galton, Francis (1822 — 1911) Galvani, Luigi (1737 — 1798) galvanizing galvanometer game game theory GAMES AND PUZZLES gamete gametophyte Gamma (Soviet orbiting telescope) Gamma Cassiopeiae Gamma Cassiopeiae star gamma function gamma globulin gamma rays Gamma Velorum gamma - ray burst gamma - ray satellites Gamow, George (1904 — 1968) ganglion gangrene Ganswindt, Hermann (1856 — 1934) Ganymede «garbage theory», of the origin of life Gardner, Martin (1914 — 2010) Garneau, Marc (1949 ---RRB- garnet Garnet Star (Mu Cephei) Garnet Star Nebula (IC 1396) garnierite Garriott, Owen K. (1930 ---RRB- Garuda gas gas chromatography gas constant gas giant gas laws gas - bounded nebula gaseous nebula gaseous propellant gaseous - propellant rocket engine gasoline Gaspra (minor planet 951) Gassendi, Pierre (1592 — 1655) gastric juice gastrin gastrocnemius gastroenteritis gastrointestinal tract gastropod gastrulation Gatewood, George D. (1940 ---RRB- Gauer - Henry reflex gauge boson gauge theory gauss (unit) Gauss, Carl Friedrich (1777 — 1855) Gaussian distribution Gay - Lussac, Joseph Louis (1778 — 1850) GCOM (Global Change Observing Mission) Geber (c. 720 — 815) gegenschein Geiger, Hans Wilhelm (1882 — 1945) Geiger - Müller counter Giessler tube gel gelatin Gelfond's theorem Gell - Mann, Murray (1929 ---RRB- GEM «gemination,» of martian canals Geminga Gemini (constellation) Gemini Observatory Gemini Project Gemini - Titan II gemstone gene gene expression gene mapping gene pool gene therapy gene transfer General Catalogue of Variable Stars (GCVS) general precession general theory of relativity generation ship generator Genesis (inflatable orbiting module) Genesis (sample return probe) genetic code genetic counseling genetic disorder genetic drift genetic engineering genetic marker genetic material genetic pool genetic recombination genetics GENETICS AND HEREDITY Geneva Extrasolar Planet Search Program genome genome, interstellar transmission of genotype gentian violet genus geoboard geode geodesic geodesy geodesy satellites geodetic precession Geographos (minor planet 1620) geography GEOGRAPHY Geo - IK geologic time geology GEOLOGY AND PLANETARY SCIENCE geomagnetic field geomagnetic storm geometric mean geometric sequence geometry GEOMETRY geometry puzzles geophysics GEOS (Geodetic Earth Orbiting Satellite) Geosat geostationary orbit geosynchronous orbit geosynchronous / geostationary transfer orbit (GTO) geosyncline Geotail (satellite) geotropism germ germ cells Germain, Sophie (1776 — 1831) German Rocket Society germanium germination Gesner, Konrad von (1516 — 1565) gestation Get Off the Earth puzzle Gettier problem geyser g - force GFO (Geosat Follow - On) GFZ - 1 (GeoForschungsZentrum) ghost crater Ghost Head Nebula (NGC 2080) ghost image Ghost of Jupiter (NGC 3242) Giacconi, Riccardo (1931 ---RRB- Giacobini - Zinner, Comet (Comet 21P /) Giaever, Ivar (1929 ---RRB- giant branch Giant Magellan Telescope giant molecular cloud giant planet giant star Giant's Causeway Giauque, William Francis (1895 — 1982) gibberellins Gibbs, Josiah Willard (1839 — 1903) Gibbs free energy Gibson, Edward G. (1936 ---RRB- Gilbert, William (1544 — 1603) gilbert (unit) Gilbreath's conjecture gilding gill gill (unit) Gilruth, Robert R. (1913 — 2000) gilsonite gimbal Ginga ginkgo Giotto (ESA Halley probe) GIRD (Gruppa Isutcheniya Reaktivnovo Dvisheniya) girder glacial drift glacial groove glacier gland Glaser, Donald Arthur (1926 — 2013) Glashow, Sheldon (1932 ---RRB- glass GLAST (Gamma - ray Large Area Space Telescope) Glauber, Johann Rudolf (1607 — 1670) glaucoma glauconite Glenn, John Herschel, Jr. (1921 ---RRB- Glenn Research Center Glennan, T (homas) Keith (1905 — 1995) glenoid cavity glia glial cell glider Gliese 229B Gliese 581 Gliese 67 (HD 10307, HIP 7918) Gliese 710 (HD 168442, HIP 89825) Gliese 86 Gliese 876 Gliese Catalogue glioma glissette glitch Global Astrometric Interferometer for Astrophysics (GAIA) Global Oscillation Network Group (GONG) Globalstar globe Globigerina globular cluster globular proteins globule globulin globus pallidus GLOMR (Global Low Orbiting Message Relay) GLONASS (Global Navigation Satellite System) glossopharyngeal nerve Gloster E. 28/39 glottis glow - worm glucagon glucocorticoid glucose glucoside gluon Glushko, Valentin Petrovitch (1908 — 1989) glutamic acid glutamine gluten gluteus maximus glycerol glycine glycogen glycol glycolysis glycoprotein glycosidic bond glycosuria glyoxysome GMS (Geosynchronous Meteorological Satellite) GMT (Greenwich Mean Time) Gnathostomata gneiss Go Go, No - go goblet cell GOCE (Gravity field and steady - state Ocean Circulation Explorer) God Goddard, Robert Hutchings (1882 — 1945) Goddard Institute for Space Studies Goddard Space Flight Center Gödel, Kurt (1906 — 1978) Gödel universe Godwin, Francis (1562 — 1633) GOES (Geostationary Operational Environmental Satellite) goethite goiter gold Gold, Thomas (1920 — 2004) Goldbach conjecture golden ratio (phi) Goldin, Daniel Saul (1940 ---RRB- gold - leaf electroscope Goldstone Tracking Facility Golgi, Camillo (1844 — 1926) Golgi apparatus Golomb, Solomon W. (1932 — 2016) golygon GOMS (Geostationary Operational Meteorological Satellite) gonad gonadotrophin - releasing hormone gonadotrophins Gondwanaland Gonets goniatite goniometer gonorrhea Goodricke, John (1764 — 1786) googol Gordian Knot Gordon, Richard Francis, Jr. (1929 — 2017) Gore, John Ellard (1845 — 1910) gorge gorilla Gorizont Gott loop Goudsmit, Samuel Abraham (1902 — 1978) Gould, Benjamin Apthorp (1824 — 1896) Gould, Stephen Jay (1941 — 2002) Gould Belt gout governor GPS (Global Positioning System) Graaf, Regnier de (1641 — 1673) Graafian follicle GRAB graben GRACE (Gravity Recovery and Climate Experiment) graceful graph gradient Graham, Ronald (1935 ---RRB- Graham, Thomas (1805 — 1869) Graham's law of diffusion Graham's number GRAIL (Gravity Recovery and Interior Laboratory) grain (cereal) grain (unit) gram gram - atom Gramme, Zénobe Théophile (1826 — 1901) gramophone Gram's stain Gran Telescopio Canarias (GTC) Granat Grand Tour grand unified theory (GUT) Grandfather Paradox Granit, Ragnar Arthur (1900 — 1991) granite granulation granule granulocyte graph graph theory graphene graphite GRAPHS AND GRAPH THEORY graptolite grass grassland gravel graveyard orbit gravimeter gravimetric analysis Gravitational Biology Facility gravitational collapse gravitational constant (G) gravitational instability gravitational lens gravitational life gravitational lock gravitational microlensing GRAVITATIONAL PHYSICS gravitational slingshot effect gravitational waves graviton gravity gravity gradient gravity gradient stabilization Gravity Probe A Gravity Probe B gravity - assist gray (Gy) gray goo gray matter grazing - incidence telescope Great Annihilator Great Attractor great circle Great Comets Great Hercules Cluster (M13, NGC 6205) Great Monad Great Observatories Great Red Spot Great Rift (in Milky Way) Great Rift Valley Great Square of Pegasus Great Wall greater omentum greatest elongation Green, George (1793 — 1841) Green, Nathaniel E. Green, Thomas Hill (1836 — 1882) green algae Green Bank Green Bank conference (1961) Green Bank Telescope green flash greenhouse effect greenhouse gases Green's theorem Greg, Percy (1836 — 1889) Gregorian calendar Grelling's paradox Griffith, George (1857 — 1906) Griffith Observatory Grignard, François Auguste Victor (1871 — 1935) Grignard reagent grike Grimaldi, Francesco Maria (1618 — 1663) Grissom, Virgil (1926 — 1967) grit gritstone Groom Lake Groombridge 34 Groombridge Catalogue gross ground, electrical ground state ground - track group group theory GROUPS AND GROUP THEORY growing season growth growth hormone growth hormone - releasing hormone growth plate Grudge, Project Gruithuisen, Franz von Paula (1774 — 1852) Grus (constellation) Grus Quartet (NGC 7552, NGC 7582, NGC 7590, and NGC 7599) GSLV (Geosynchronous Satellite Launch Vehicle) g - suit G - type asteroid Guericke, Otto von (1602 — 1686) guanine Guiana Space Centre guidance, inertial Guide Star Catalog (GSC) guided missile guided missiles, postwar development Guillaume, Charles Édouard (1861 — 1938) Gulf Stream (ocean current) Gulfstream (jet plane) Gullstrand, Allvar (1862 — 1930) gum Gum Nebula gun metal gunpowder Gurwin Gusev Crater gut Gutenberg, Johann (c. 1400 — 1468) Guy, Richard Kenneth (1916 ---RRB- guyot Guzman Prize gymnosperm gynecology gynoecium gypsum gyrocompass gyrofrequency gyropilot gyroscope gyrostabilizer Gyulbudagian's Nebula (HH215)

China leads the total number of clinical - stage CAR - T cell therapies, whereas US has the largest number of pre-clinical agents.

Derivation of pluripotent stem cells, either of embryonic origin or following genetic reprogramming, has opened the path for an alternative source for epidermal cell therapy as these cells are both immortal and pluripotent, theoretically capable of providing any requested number of cells of any desired phenotype.

Through the UCSD Clinical Cardiovascular Cell Therapy program, Dib and collaborating cardiology faculty plan to conduct clinical studies in a number of areas, including the effectiveness of adult stem cell transplant as a treatment for congestive heart failure; as a way to minimize heart damage after a heart attack; and in the formation of new blood vessels (angiogenesis) to increase blood flow to the heart for patients experiencing chest pCell Therapy program, Dib and collaborating cardiology faculty plan to conduct clinical studies in a number of areas, including the effectiveness of adult stem cell transplant as a treatment for congestive heart failure; as a way to minimize heart damage after a heart attack; and in the formation of new blood vessels (angiogenesis) to increase blood flow to the heart for patients experiencing chest pcell transplant as a treatment for congestive heart failure; as a way to minimize heart damage after a heart attack; and in the formation of new blood vessels (angiogenesis) to increase blood flow to the heart for patients experiencing chest pain.

Success is totally dependent on resolving a number of factors unique to cells as therapies, including: manufacturing, enabling technologies, regulation, reimbursement and essential infrastructure.

But efforts to develop adoptive T cell therapies for solid tumors have hit upon a number of challenges; the only gene therapies to show significant benefit for patients have been in liquid tumors — forms of leukemia and lymphoma.

Often the feasibility of using stem cells for regenerative therapies is limited by two factors: obtaining a significant number of cells and doing so in a relatively noninvasive manner.

It aims at producing cell lines that are to be broadly available for manufacturing cell therapies matching the widest possible number of récipients.

Not so long ago, human embryonic stem cell (hESC) research and SCNT were being hailed as the future of regenerative medicine, capable of generating cures and therapies for any number of diseases and conditions.

A number of adult stem cell therapies already exist, particularly bone marrow transplants that are used to treat leukemia.

«The successful retrieval of memories in AD mice by increasing the number of spines for normal memory processing only in the memory cells, rather than in a broad population of cells, highlights the importance of highly - targeted manipulation of neurons and their circuits for future therapies,» said Tonegawa in a statement.

Future therapies will have to be based on strategies that act by reducing or increasing the number or activity of specific subtypes of pre - and postsynaptic receptors, transporters, and ion channels, or other membrane molecules at the synapse, and by strategies that exploit the new possibilities offered by stem cell technology and targeted repair.

The findings have implications for the design of cancer vaccines and what are called adoptive T cell therapies; when T cells are collected from a patient and grown in the laboratory, increasing in number before they are given back to the patient to help the immune system fight disease.

Chris is on a number of national and international committees, working groups and initiatives related to the academic, clinical translation and commercialization of cell and gene therapies including; Founder and CEO of the London Regenerative Medicine Network (LRMN), Founding Member of the UK - Israel Science Council, Scientific Advisory Board of the UK Cell and Gene Therapy Catapult, Strategic Advisory Board of the Canadian Centre for the Commercialization of Regenerative Medicine (CCRM), and Scientific Advisory Board of the Canadian Stem Cell Netwcell and gene therapies including; Founder and CEO of the London Regenerative Medicine Network (LRMN), Founding Member of the UK - Israel Science Council, Scientific Advisory Board of the UK Cell and Gene Therapy Catapult, Strategic Advisory Board of the Canadian Centre for the Commercialization of Regenerative Medicine (CCRM), and Scientific Advisory Board of the Canadian Stem Cell NetwCell and Gene Therapy Catapult, Strategic Advisory Board of the Canadian Centre for the Commercialization of Regenerative Medicine (CCRM), and Scientific Advisory Board of the Canadian Stem Cell NetwCell Network.

Adult stem cell therapy has been shown in a number of clinical trials to slow and, in some cases, even reverse heart deterioration in patients with coronary artery disease (CAD).

Based on positive results produced from a number of scientific clinical trials, coronary artery disease therapy using adult stem cells is a promising new method of treatment for coronary artery disease patients.

These findings will enable increasing numbers of researchers across the world to use these stem - cell like cells to study disease and explore potential regenerative therapies.

A limited number of activities will also be directed toward the public to promote the level of understanding for informed decisions and to present the possibilities and problems that surround stem cell therapies for neurodegenerative diseases.

We will explore topics such as how policies differ globally, the challenge of steering through the regulatory landscape for both academic researchers and manufacturers, and the number of unproven cell therapies being advertised on the market.

Cell therapies are a growing area of interest for the treatment of a number of indications such as neurological, cardiovascular, and ophthalmological maladies that are refractory to other more conventional drug therapies.

UNITY is developing a number of therapies intended to selectively eliminate senescent cells and restore tissue to a more functionally healthy state, thereby addressing the underlying causes of age - associated diseases.

To inform further DST development for cell therapies, we examined existing process systems along a number of dimensions: e.g., cell type, process scale, modeling techniques used, and degree of validation.

A number of treatments exist, including enzyme replacement therapy and hematopoietic stem cell transplantation, but efficacy depends upon diagnosing the disease and its specific form as early as possible.

Therapy using live cells is increasingly used to replace damaged tissue, deliver gene therapies to target tissues and organs, and stimulate self - healing along with a number of other applications.

In Sabrina's poster, she showed that patients with a low number of different types of T - cells (a type of immune cell which has different versions to fight different infections / diseases; called a T - cell repertoire or TCR) in their blood at start of treatment were more likey to respond to anti-PD1 therapy, and had a poor response to anti-CTLA4 therapy.

December 13, 2011 Molecular markers can predict spread of cancer, guide treatment Molecular markers found in cancer cells that have spread from a primary tumor to a limited number of distant sites can help physicians predict which patients with metastatic cancer will benefit from aggressive, targeted radiation therapy.

They suggest that further research should be performed over a longer time period and in a greater number of animals to determine whether these improvements are maintained, and look forward to further work utilizing membrane - spanning peptides for presentation of bioactive molecules for stem cell therapy.

Additionally, the greater the number of these trunk neoantigens, the more likely the patient will respond to immune checkpoint inhibitor therapy, an antibody - based intervention that unleashes T cells to attack tumors.

And the good news is there are a number of treatment options available including camouflage using make - up and self tanning lotions; micro-tattooing may be useful for small stable areas of vitiligo such as face, lips and hands; light therapy; the transfer of a patient's own pigment cells from unaffected skin into the vitiligo - affected cells and laser treatments.

With a minimal 2 - hour therapy period, this study found that castor oil packs produced a «significant» temporary increase in the number of T - 11 cells that increased over a 7 hour period following treatment and then returned to normal levels within 24 hours later.